Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase III, Phase II	Treatment	Active	4 to 70	Other	RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15

Trial Description

Purpose:

Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient’s immune system from rejecting the donor’s stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known which combination chemotherapy regimen is most effective when given before a donor stem cell transplant in treating aplastic anemia or hematologic cancer.

This phase II/III trial is studying different combination chemotherapy regimens to compare how well work when given before donor stem cell transplant in treating patients with aplastic anemia or hematologic cancer.

Eligibility:

Eligibility criteria include the following:

• 4-70 years old
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive different combination chemotherapy regimens by infusion for up to 6 days. Some patients may also receive total-body irradiation twice a day for 3 days. All patients will then receive donor stem cells. Some patients may receive radiation therapy 4-8 weeks after transplant.

Patients will be evaluated periodically after transplant.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Roswell Park Cancer Institute

Philip McCarthy, MD, Protocol chair		Ph: 716-845-4074; 800-685-6825 Email: philip.mccarthy@roswellpark.org

U.S.A.
New York
	Buffalo
	Roswell Park Cancer Institute
		Clinical Trials Office - Roswell Park Cancer Institute	Ph:  877-275-7724

Registry Information
Official Title		Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia
Trial Start Date		1998-10-19
Trial Completion Date		2012-07-28 (estimated)
Registered in ClinicalTrials.gov		NCT00003816
Date Submitted to PDQ		1999-03-12
Information Last Verified		2008-11-30
NCI Grant/Contract Number		CA16056